|Bid||29.45 x 1100|
|Ask||0.00 x 1100|
|Day's Range||30.24 - 30.49|
|52 Week Range||24.54 - 30.84|
|PE Ratio (TTM)||398.82|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.76|
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The virtual world has changed the patient-doctor relationship as men and women ranging from millennials to seniors explore options in health care outside the traditional doctor’s office or hospital.
Zacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and Celanese
MARLBOROUGH, Mass. , May 16, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of key presentations, including two late-breaking clinical trials, that will be ...
The equity markets continued to breathe easy as the U.S.-China trade concerns abated with President Trump pledging support for the beleaguered Chinese telecom firm, ZTE, and the Qualcomm-NXP merger review process getting a roll-on with urgency from the top administration of China. A high ROE ensures that the company is reinvesting its cash at a high rate of return. ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
This takes a look at the gynecological mesh, how it has affected women it was placed in, and the 48,000 lawsuits concerning it. The first bit of bad publicity for Boston Scientific is what has been happening to the gynecological mesh over time. The report then looks at how Boston Scientific makes the gynecological mesh.
MARLBOROUGH, Mass. , May 14, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 34 th Annual Strategic Decisions Conference on May 31, 2018 in New York . ...
MARLBOROUGH, Mass., May 11, 2018 /PRNewswire/ -- Boston Scientific (BSX) today announced results from an analysis of the LATITUDE database which evaluated the successful reduction of inappropriate shocks using the SMART Pass sensing filter in patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The real-world data were presented during a late-breaking clinical trial at Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions in Boston, and demonstrated that when the sensing filter was in use, the rate of inappropriate shocks was reduced to 4.3% at one year.
An increasingly common cardiovascular procedure using a device made by several medical technology companies was no better than drug therapy at preventing deaths, strokes and certain other complications, a new study found. The outcome of the trial raises questions about the procedure, known as catheter ablation, to treat patients with atrial fibrillation. Abbott Laboratories, Johnson & Johnson, Medtronic PLC and Boston Scientific Corp. make the device used in the procedure.
Boston Scientific Corporation (NYSE:BSX) delivered a less impressive 1.59% ROE over the past year, compared to the 11.43% return generated by its industry. Though BSX’s recent performance is underwhelming, itRead More...
On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.
MARLBOROUGH, Mass. , May 7, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2018 Health Care Conference on May 16, 2018 in ...
(Continued from Prior Part)ABT’s Medical Device business In 1Q18, Abbott Laboratories (ABT) registered sales of $7.4 billion, representing YoY (year-over-year) growth of ~16.7%. The company’s Medical Device segment registered strong growth and contributed ~37.0% to the company’s total sales, the highest of all four of its segments. ABT’s Medical Device segment sales came in at ~$2.7 billion in 1Q18. On a reported basis, the segment’s sales growth was ~14.6% on a YoY basis. However, on an organic basis, the segment’s sales increased ~9.4%. ...
On April 18, Abbott Laboratories (ABT) released its 1Q18 earnings results. The company registered revenues of $7.4 billion, which represents YoY (year-over-year) growth of ~16.7%. These sales results exceeded analysts’ estimates.
On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.
Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.
MARLBOROUGH, Mass., April 30, 2018 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced the close of its acquisition of NxThera. The company developed the Rezūm® system, a minimally invasive therapy (MIT) for patients with symptomatic benign prostatic hyperplasia (BPH). With the completion of the acquisition, NxThera will become part of the Boston Scientific Urology and Pelvic Health business.
On April 25, Thermo Fisher Scientific (TMO) announced its earnings results for 1Q18, which ended on March 31. Its revenues grew ~23% to ~$5.9 billion YoY (year-over-year). The sales results came in ahead of analysts’ estimate of ~$5.6 billion.
On April 25, Boston Scientific announced its 1Q18 earnings results. Boston Scientific’s results exceeded analysts’ estimates and the company guidance. During the earnings release, Boston Scientific updated its outlook for fiscal 2018. The company expects to register fiscal 2018 sales of $9.75 billion–$9.9 billion. The EPS (earnings per share) in fiscal 2018 is expected to be $1.37–$1.41.
Yahoo Finance's Jared Blikre joins Seana Smith from the New York Stock Exchange to discuss the latest market moves.